Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

EGF receptor inhibition: attacks on multiple fronts.

Stevan R Hubbard1

  • 1Structural Biology Program, Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, New York 10016, USA. hubbard@saturn.med.nyu.edu <hubbard@saturn.med.nyu.edu>

Cancer Cell
|April 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Janus kinase 2 activation loop as a regulator of catalysis and trans-activation.

International journal of biological macromolecules·2026
Same author

Catalytic activities of wild-type C. elegans DAF-2 kinase and dauer-associated mutants.

The FEBS journal·2024
Same author

Biochemical characterization of the Drosophila insulin receptor kinase and longevity-associated mutants.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2023
Same author

New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.

Cell chemical biology·2023
Same author

Structural basis of Janus kinase trans-activation.

Cell reports·2023
Same author

Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain.

Pharmaceuticals (Basel, Switzerland)·2023

This study reveals how the drug cetuximab inhibits epidermal growth factor receptor (EGFR) by blocking its ligand-binding domain. This molecular understanding is key for developing targeted therapies for epithelial carcinomas.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Epidermal growth factor receptor (EGFR) signaling promotes tumor progression in various human epithelial cancers.
  • Cetuximab (Erbitux) is an FDA-approved monoclonal antibody therapy for advanced colorectal cancers.
  • The precise mechanism of cetuximab's inhibition of EGFR has been under investigation.

Purpose of the Study:

  • To elucidate the molecular mechanism by which cetuximab inhibits EGFR activity.
  • To provide a structural basis for understanding EGFR-targeted therapy.

Main Methods:

  • X-ray crystallography was employed to determine the structure of EGFR in complex with cetuximab.
  • Analysis of the crystal structure revealed the binding site and interaction of cetuximab with EGFR.

Related Experiment Videos

Main Results:

  • The crystallographic study identified that cetuximab binds to a specific ligand-binding domain of EGFR.
  • This binding event sterically hinders the interaction of natural ligands with the receptor.
  • The interaction prevents the activation of the EGFR signaling pathway.

Conclusions:

  • Cetuximab functions by physically blocking ligand binding to the EGFR extracellular domain.
  • This structural insight explains the therapeutic efficacy of cetuximab in EGFR-driven cancers.
  • The findings support the rational design of future EGFR-targeted inhibitors.